Associations Between Cardiovascular Events and Nonergot Dopamine Agonists in Parkinson's Disease.

ABSTRACT:

Background

Knowledge of possible cardiovascular risks from Parkinson's disease (PD) medications is critical to informing safe and effective treatment decisions. The objective of our study was to determine whether PD patients treated with nonergot dopamine agonists (DAs) are at increased risk of adverse cardiovascular or cerebrovascular outcomes, relative to PD patients receiving other treatments.

Methods

Matched case-control studies were conducted within a cohort of 14,122 inpatients receiving treatment for PD who were identified in the Cerner Health Facts database. Primary outcomes were associations between nonergot DA use and diagnosis of adverse cardiovascular events (acute myocardial infarction, heart failure [HF], hypotension, and valvulopathy). Secondary outcomes inclu

SUBMITTER: Crispo JAG 

PROVIDER: S-EPMC6178630 | biostudies-literature | 2016 May-Jun

REPOSITORIES: biostudies-literature